Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial
| Autor: | Bountouroglou N, J. Glotsos, Nikolaos Ziras, N. Mitakidis, N. Karvounis, Athanassiou Ae, A. Kouloubinis, D.G. Pectasides |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male medicine.medical_specialty Paclitaxel medicine.medical_treatment Docetaxel Deoxycytidine Gastroenterology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoadjuvant therapy Aged Carcinoma Transitional Cell Chemotherapy Performance status business.industry Hematology Middle Aged medicine.disease Gemcitabine Chemotherapy regimen Surgery Regimen Urinary Bladder Neoplasms Oncology Female Taxoids Cisplatin business Febrile neutropenia medicine.drug |
| Zdroj: | Annals of Oncology. 13:243-250 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdf017 |
| Popis: | Purpose To evaluate the efficacy and toxicity of a combination of weekly docetaxel, gemcitabine and cisplatin in advanced transitional cell carcinoma (TCC) of the bladder. Patients and methods Thirty-five chemotherapy-naive (adjuvant and neoadjuvant chemotherapy was allowed) patients with advanced TCC received intravenous docetaxel 35 mg/m2, gemcitabine 800 mg/m2and cisplatin 35 mg/m2, on days 1 and 8 every 3 weeks. Prophylactic granulocyte-colony stimulating factor was given from days 3 to 6 and days 10 to 15; anti-emetics were used routinely. Results Most (27) patients (77.1%) had a performance status of 0 to 1 and eight (22.9%) had received prior adjuvant or neoadjuvant cisplatin-based chemotherapy. In the intention-to-treat analysis, the objective response rate was 65.6% [23/35 patients, 95% confidence interval (CI) 47.8% to 80.9%]. Ten patients (28.5%) achieved a complete response (95% CI 14.6% to 46.3%) and 13 (37.1%) a partial response (95% CI 21.5% to 55.0%). Median survival time was 15.5 months, median duration of response was 10.2 months and median time to progression was 8.9 months. Ten patients (28.5%) developed grade 3/4 neutropenia, including five (14.3%) who experienced febrile neutropenia, which was successfully treated. Grade 3/4 anaemia and thrombocytopenia occurred in 20% and 25.7% of patients, respectively; four patients required platelet transfusions. There were no treatment-related deaths. Conclusions Weekly docetaxel, gemcitabine plus cisplatin is a highly effective treatment for chemotherapy-naive advanced TCC, and causes only moderate toxicity. This regimen should be considered as a suitable option that deserves further prospective evaluation through randomised phase III trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|